Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

BU researchers find how SARS-CoV-2 infection may drive deadly lung inflammation

Responding to the COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, requires models that can duplicate disease development in humans, identify potential targets and enable drug testing.

21 Sep 2020

Flu vaccine does not increase a person's COVID-19 risk, finds study

A new Cleveland Clinic study has found that receiving the influenza vaccine does not increase a person's risk for contracting COVID-19 or worsen associated morbidity or mortality.

21 Sep 2020

Without Ginsburg, judicial threats to the ACA, reproductive rights heighten

On Feb. 27, 2018, I got an email from the Heritage Foundation, alerting me to a news conference that afternoon held by Republican attorneys general of Texas and other states. It was referred to only as a "discussion about the Affordable Care Act lawsuit."

21 Sep 2020

Trump-Biden race could hinge on how Florida’s Pinellas County swings

Betty Jones voted for President Donald Trump in 2016, but the lifelong Republican has her doubts she will do it again this year.

21 Sep 2020

California’s deadliest spring in 20 years suggests COVID undercount

The first five months of the COVID-19 pandemic in California rank among the deadliest in state history, deadlier than any other consecutive five-month period in at least 20 years.

21 Sep 2020

CDC updates coronavirus guidelines to recognize airborne spread

Early on in the pandemic, it was thought that the virus was only spread via respiratory droplets. However, scientific research soon showed it also to be an airborne virus. Now, the U.S. Centers for Disease Control and Prevention (CDC) has updated its guideline, acknowledging that the virus can hang in the air, fueling its spread.

21 Sep 2020

Researchers analyze kits to detect and inactivate COVID-19

The nation's ability to test for COVID-19 has expanded, thanks to work at the U.S. Department of Energy's Pacific Northwest National Laboratory in collaboration with the University of Washington.

21 Sep 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Chinese workers knowledge, attitudes and practices regarding COVID-19

In new research, scientists in China have looked at the knowledge, attitudes, and practices regarding COVID-19 among Chinese workers. The research paper titled, “Knowledge, attitudes, and practices related to Coronavirus disease 2019 during the outbreak among workers in China: A large cross-sectional study,” is published in the latest issue of the journal PLOS Neglected Tropical Diseases.

20 Sep 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Among them is the combination of lopinavir and ritonavir, which have been in use in an attempt to reduce the severity of the disease. However, a new South Korean study published on the preprint server bioRxiv in September 2020 shows that this combination is ineffective against the virus.

20 Sep 2020

Study identifies new regions of positive selection in SARS-CoV-2

Based on structural modeling of ribonucleic acid (RNA) and proteins, the researchers from Duke University argue that newly identified regions of positive selection in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) likely affect species-specific RNA instead of protein function – improving our understanding of the molecular mechanisms responsible for highly unique biological properties of this virus.

20 Sep 2020

Researchers try and pop SARS-CoV-2 with an AFM tip - virion surprisingly resilient

Researchers at Semmelweis University and the National Public Health Center in Hungary have conducted an imaging study showing that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for coronavirus disease 2019 (COVID-19), is a highly dynamic and resilient virus

20 Sep 2020